Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO safety report database

Regulatory Toxicology and Pharmacology

Volumn 70, Issue 2, 2014, Pages 519-526

  Hunt, Christine M ^a,b   Yuen, Nancy A ^c   Stirnadel Farrant, Heide A ^d   Suzuki, Ayako ^e,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Acute liver failure; Aging; Cholestatic injury; Data mining; Drug induced liver injury; Hepatotoxicity; Lipophilicity; Mitochondrial dysfunction; Pediatric

Indexed keywords

ABACAVIR; ALLOPURINOL; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; BOSENTAN; CARBAMAZEPINE; CARBIMAZOLE; CHLORPROMAZINE; CYPROTERONE; DANAZOL; DAPSONE; DIDANOSINE; ETHAMBUTOL; FLUCLOXACILLIN; FLUCONAZOLE; FUSIDIC ACID; HYDROCODONE; INDINAVIR; ISONIAZID; JOSAMYCIN; MERCAPTOPURINE; METHOTREXATE; MINOCYCLINE; NIMESULIDE; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; ROXITHROMYCIN; UNINDEXED DRUG;

ACUTE LIVER FAILURE; ADOLESCENT; ADULT; AGE; ARTICLE; BILIARY EXCRETION; CHILD; DATA BASE; DATA MINING; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SURVEILLANCE PROGRAM; HUMAN; INFANT; LIPOPHILICITY; LIVER CELL DAMAGE; LIVER INJURY; MAJOR CLINICAL STUDY; NEWBORN; PHENOTYPE; TOXIC HEPATITIS; WORLD HEALTH ORGANIZATION; AGED; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; LIVER; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATA MINING; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT; INFANT, NEWBORN; LIVER; MIDDLE AGED; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84907468630     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2014.09.007     Document Type: Article

References (86)

1. Alfirevic A., Pirmohamed M. Drug induced hypersensitivity and the HLA complex. Pharmaceuticals 2010, 4:69-90.
2. Almenoff J.S., Tonning J.M., Gould A.L., et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005, 28:981-1007.
3. Almenoff J.S., LaCroix K.K., Yuen N.A., et al. Comparative performance of two quantitative safety signalling methods. Drug Saf. 2006, 29:875-887.
4. Apostolova N., Blas-García A., Esplugues J.V. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol. Sci. 2011, 32:715-725.
5. Arrow Roxithromycin (U.S. Census Bureau, 2013). http://www.medsafe.govt.nz/profs/datasheet/a/ArrowRoxithromycintab.pdf (accessed 8.08.13). http://www.medsafe.govt.nz/profs/datasheet/a/ArrowRoxithromycintab.pdf.
6. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin. Pharmacokinet. 1998, 35:247-274.
7. Bode K.A., Donner M.G., Leier I., et al. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem. Pharmacol. 2002, 64:151-158.
8. Boelsterli U.A. Mechanisms of NSAID-induced hepatotoxicity. Drug Saf. 2002, 25:633-648.
9. Caster O., Conforti A., Viola E., et al. Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur. J. Clin. Pharmacol. 2014, 1-3.
10. Chem Exper Chemical Directory at: (accessed 8.08.13). https://www.chemexper.com.
11. Chen L.H., Chiou G.Y., Chen Y.W., et al. MicroRNA and aging: a novel modulator in regulating the aging network. Ageing Res. Rev. 2010, 9:S59-S66.
12. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58:388-396.
13. Cheung C.K., Wyman J.F., Halcon L.L. Use of complementary and alternative therapies in community-dwelling older adults. J. Altern. Complement. Med. 2007, 13:997-1006.
14. Chew G.Y.J., Hawkins C.A., Cherian M., et al. Roxithromycin induced hypersensitivity pneumonitis. Pathology 2006, 38:475-477.
15. Chowdhury A., Santra A., Bhattacharjee K., et al. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 2006, 45:117-126.
16. DailyMed. (accessed 18.0813). http://dailymed.nlm.nih.gov.
17. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Drug Metab. Rev. 2012, 44:116-126.
18. Dawson S., Stahl S., Paul N., et al. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 2012, 40:130-138.
19. de Abajo F.J., Montero D., Madurga M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol. 2004, 58:71-80.
20. Drug Information Online. (accessed 8.08.13). http://www.drugs.com/cons/fusidic-acid-oral-injection.html.
21. Dykens J.A., Marroquin L.D., Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 2007, 7:161-175.
22. Evered D.C. Endocrine and metabolic diseases. Treatment of thyroid disease: I. Br. Med. J. 1976, 1:264-266.
23. Ferrajolo C., Capuano A., Verhamme K., et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br. J. Clin. Pharmacol. 2010, 70:721-728.
24. Food and Drug Administration Import Refusal Report: Josamycin. (accessed 24.09.13). http://www.accessdata.fda.gov/scripts/importrefusals/ir_detail.cfm?EntryId=DO7-0110115-9%26DocId=1%26LineId=1%26SfxId=.
25. Forget E.J., Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 2006, 5:231-249.
26. Freymond N., Catelain A., Cousin F., et al. Skin delayed-type hypersensitivity to josamycin. Allergy 2003, 58:1319-1320.
27. Grolleau-Julius A., Ray D., Yung R.L. The role of epigenetics in aging and autoimmunity. Clin. Rev. Allergy Immunol. 2010, 39:42-50.
28. Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse Drug events among older persons in the ambulatory setting. JAMA 2003, 289:1107-1116. 10.1001/jama.289.9.1107.
29. Hohensinner P.J., Goronzy J.J., Weyand C.M. Telomere dysfunction, autoimmunity and aging. Aging Dis. 2011, 2:524.
30. Horio T. Chlorpromazine photoallergy: coexistence of immediate and delayed type. Arch. Dermatol. 1975, 111:1469.
31. Huang Y.S. Recent global endeavors in the detection and prevention of drug-induced liver injury. J. Formos. Med. Assoc. 2012, 111:237-238.
32. Hunt C.M., Strater S. Effect of normal aging on the activity of Human Hepatic Cytochrome P-4502E1. Biochem. Pharmacol. 1990, 40:1666-1669.
33. Hunt C.M., Westerkam W.R., Stave G.M., et al. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech. Ageing Dev. 1992, 64:189-199.
34. Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 1992, 44:275-283.
35. Jemnitz K., Veres Z., Tugyi R., et al. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol. In Vitro 2010, 24:605-610.
36. Kalliokoski A., Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 2009, 158:693-705.
37. Karras S., Memi E., Kintiraki E., et al. Pathogenesis of propylthiouracil-related hepatotoxicity in children: present concepts. J. Pediatr. Endocrinol. Metab. 2012, 25:623-630.
38. Kearns G.L., Abdel-Rahman S.N., Alander S.W., et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 2003, 349:1157-1167.
39. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev. 2009, 41:67-76.
40. Kuhnz W., Kulmann H., Fuhrmeister A. Investigation into the age-dependence of the pharmacokinetics of cyproterone acetate in healthy male volunteers. Eur. J. Clin. Pharmacol. 1997, 53:75-80.
41. Lammert C., Einarsson S., Saha C., et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47:2003-2009.
42. Lammert C., Bjornsson E., Niklasson A., et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
43. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf. J. 2008, 42:409-419.
44. López-Lluch G., Irusta P.M., Navas P., et al. Mitochondrial biogenesis and healthy aging. Exp. Gerontol. 2008, 43:813-819.
45. Lucena M.I., Andrade R.J., Kaplowitz N., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009, 49:2001-2009.
46. Marotta P.J., Roberts E.A. Pemoline hepatotoxicity in children. J. Pediatr. 1998, 132:894-897.
47. McFarland R., Hudson G., Taylor R.W., et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase γ (POLG1). Arch. Dis. Child. 2008, 93:151-153.
48. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the united network for organ sharing database. Liver Transpl. 2009, 15:719-729.
49. Minuesa G., Huber-Ruano I., Pastor-Anglada M., et al. Drug uptake transporters in antiretroviral therapy. Pharmacol. Ther. 2011, 132:268-279.
50. Molleston J.P., Fontana R.J., Lopez M.J., et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J. Pediatr. Gastroenterol. Nutr. 2011, 53:182-189.
51. Moore T.J., Cohen M.R., Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 2007, 167:1752-1759.
52. Morgan R.E., van Staden C.J., Chen Y., et al. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 2013, 136:216-241.
53. MHRA Drug Safety Update. (accessed 24.09.13). http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087674.
54. Murray K.F., Hadzic N., Wirth A., et al. Drug-related hepatotoxicity and acute liver failure. J. Pediatr. Gastroenterol. Nutr. 2008, 47:395-405.
55. Nadanaciva S., Dillman K., Gebhard D.F., et al. High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cells. J. Biomol. Screen. 2010, 15:937-948.
56. National Institutes of Health. LiverTox at: (accessed 18.09.13). http://livertox.nlm.nih.gov/Oxacillin.htm.
57. Norrby S.R. Antibiotic therapy in aging patients. Bull. N. Y. Acad. Med. 1987, 63:519-532.
58. Ostapowicz G., Fontana R.J., Schiødt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002, 137:947-954.
59. Ouslander J.G. Drug therapy in the elderly. Ann. Intern. Med. 1981, 95:711-722.
60. Papapetrou P.D., Marchant B., Gavras H., et al. Biliary excretion of 35 S-labelled propylthiouracil, methimazole and carbimazole in untreated and pentobarbitone pretreated rats. Biochem. Pharmacol. 1972, 21:363-370.
61. Pauli-Magnus C., Meier P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006, 44:778-787.
62. Pessayre D., Fromenty B., Berson A., et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012, 44:34-87.
63. Petronijevic M., Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™. J. Clin. Pharmacol. 2013, 53:435-443. 10.1002/jcph.3.
64. Puri S.K., Lassman H.B. Roxithromycin: a pharmacokinetic review of a macrolide. J. Antimicrob. Chemother. 1987, 20:89-100.
65. Ramappa V., Aithal G.P. Hepatotoxicity related to anti-tubercular drugs: mechanisms and management. J. Clin. Exp. Hepatol. 2012, 3:37-49.
66. Riess C.E., Bruckner-Tuderman L. Delayed type hypersensitivity to fusidic acid in patients with chronic dermatitis. Lancet 1990, 335:1525-1526.
67. Rivkees S.A., Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J. Clin. Endocrinol. Metab. 2010, 95:3260-3267.
68. Rosh J.R., Dellert S.F., Narkewicz M., et al. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. Pediatrics 1998, 101:921-923. 10.1542/peds.101.5.921.
69. Russmann S., Jetter A., Kullak-Ublick G.A. Pharmacogenetics of drug-induced liver injury. Hepatology 2010, 52:748-761.
70. Saab L., Peluso J., Muller C.D., et al. Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry. Cytometry A 2013, 83A:403-408.
71. Sakatis M.Z., Reese M.J., Harrell A.W., et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem. Res. Toxicol. 2012, 25:2067-2082.
72. Schiødt F.V., Chung R.T., Schilsky M.L., Eileen Hay J., et al. Outcome of acute liver failure in the elderly. Liver Transpl. 2009, 15:1481-1487.
73. Schmucker DL, Sanchez H, 2011. "Liver regeneration and aging: a current perspective." Current gerontology and geriatrics research. (accessed 8.08.13). http://dx.doi.org.libproxy.lib.unc.edu/10.1155/2011/526379.
74. Schwartz J.B. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin. Pharmacol. Ther. 2006, 79:440-448.
75. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
76. Squires R.H., Shneider B.L., Bucuvalas J., et al. Acute liver failure in children. Clin. Liver Dis. 2006, 10:149-168.
77. Suzuki A., Andrade R.J., Bjornsson E., et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase™. Drug Saf. 2010, 33:503-522.
78. Tachibana A., Sasaki H., Watanabe T., et al. [Absorption, distribution and excretion of 14C-josamycin and 14C-josamycin propionate in rats (author's transl)]. Jpn. J. Antibiot. 1975, 28:558.
79. Tapner N.J., Jones B.E., Wu W.M., et al. Toxicity of low dose aza-thioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J. Hepatol. 2004, 40:454-463.
80. Thompson R.A., Isin E.M., Li Y., et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. Toxicol. 2012, 25:1616-1632.
81. Turnheim K. Pharmacokinetic dosage guidelines for elderly subjects. Expert Opin. Drug Metab.& Toxicol. 2005, 1:33-48. 10.1517/17425255.1.1.33.
82. U.S. Census Bureau, at: (accessed 7.08.13). http://www.census.gov/newsroom/releases/archives/2010_census/cb12-239.html.
83. Van Steenbergen W., Peeters P., De Bondt J., et al. Nimesulide-induced acute hepatitis: evidence from six cases. J. Hepatol. 1998, 29:135-141.
84. Wolf K.K., Vora S., Webster L.O., et al. Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. Toxicol. In Vitro 2010, 24:297-309.
85. Yang K., Köck K., Sedykh A., et al. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci. 2013, 102:3037-3057.
86. Zamek-Gliszczynski M.J., Hoffmaster K.A., Tian X., et al. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab. Dispos. 2005, 33:1158-1165.